Details for Patent: 12,552,792

Which drugs does patent 12,552,792 protect, and when does it expire?

Patent 12,552,792 protects PEMAZYRE and is included in one NDA.

This patent has forty-four patent family members in thirty-three countries.

Summary for Patent: 12,552,792

Title:	Solid forms of an FGFR inhibitor and processes for preparing the same
Abstract:	The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Inventor(s):	William Frietze, Zhongjiang Jia, Ming Tao, Jiacheng Zhou
Assignee:	Incyte Corp
Application Number:	US17/931,377
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 12,552,792

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-001	Apr 17, 2020		RX	Yes	No	12,552,792		Y	Y
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-002	Apr 17, 2020		RX	Yes	No	12,552,792		Y	Y
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-003	Apr 17, 2020		RX	Yes	Yes	12,552,792		Y	Y

International Family Members for US Patent 12,552,792

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	121476
Australia	2019262195
Australia	2024278146
Brazil	112020022392
Canada	3099287
Chile	2020002839